Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary research data collected 1, 6, and 12 months after Dupixent’s launch. Along with awareness of, familiarity with, and perceptions related to Dupixent, this research assesses the trial and use, including anticipated future trends, of Dupixent. We also explore Sanofi/Regeneron’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.
What you will learn in this content:
Methodology: ~75 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.
Key drugs: Dupixent
Key companies: Sanofi, Regeneron
Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU), Atopic Dermatitis Emerging Therapy Launch Tracking Eucrisa